HuM-195 + recombinant gelonin

HuM-195 + recombinant gelonin is an experimental immunotoxin designed for the treatment of myeloid malignancies, specifically targeting CD33-expressing cells. The drug consists of the humanized monoclonal antibody HuM-195 (lintuzumab), which is directed against the CD33 antigen, chemically conjugated to recombinant gelonin (rGel). Gelonin is a Type I ribosome-inactivating protein (RIP) derived from the seeds of *Gelonium multiflorum*. Upon administration, the HuM-195 component binds to CD33 on the surface of leukemic blasts, triggering receptor-mediated endocytosis. Once internalized, the gelonin toxin is released into the cytoplasm where it enzymatically removes a specific adenine residue from the sarcin/ricin loop of the 28S ribosomal RNA. This irreversible damage to the 60S ribosomal subunit permanently halts protein synthesis, leading to cell death via apoptosis. This targeted delivery mechanism is intended to reduce the systemic toxicity typically associated with standard chemotherapy for acute myeloid leukemia.

Other names

lintuzumab-geloninHuM-195-geloninHuM195-geloninHuM 195-geloninCD33-gelonin immunotoxinCD-33-gelonin immunotoxinCD 33-gelonin immunotoxin